Introduction {#sec1-1}
============

Generalized epilepsy with febrile seizure plus (GEFS+) which was firstly described by Scheffer and Berkovic (1997) is a familial epilepsy syndrome characterized by heterogenous phenotypes of focal and generalized epileptic seizures and genetically heterogenous.\[[@ref1]--[@ref3]\] Individuals with GEFS+ developed febrile seizures in early childhood (less than 6 months of age) and continues beyond 6 years of age with the presence and absence of fever.\[[@ref4]\] The clinical phenotype is variable and ranges from mild febrile seizures, febrile seizure plus (FS+) to less commonly; afebrile seizures with atonic, myoclonic, or absences seizures.\[[@ref3]--[@ref7]\] GEFS+ is genetically heterogenous with evidence of the involvement of various sodium channels; *SCN1A*, *SCN1B*, and *SCN2A* (encoding alpha 1, alpha 2, and beta 1 voltage-gated sodium channel subunits) and *GABA*~A~ receptors; *GABRG2* and *GABRD* subunit identified to date that cause GEFS+.\[[@ref8]--[@ref11]\] Most significant GEFS+ gene, *SCN1A*, accounts for more than 300 mutations associated with the broader spectrum of GEFS+ including myoclonic-astatic epilepsy, severe myoclonic epilepsy of infancy (Dravet syndrome), and infantile spasms.\[[@ref3][@ref7][@ref12]\] A 15-year-old boy with GEFS+ harboring a novel point c.5197A \> G in exon 26 of *SCN1A* who presented variable phenotypic expression is described.

Case Report {#sec1-2}
===========

This 15-year-old Malay boy born to non-consanguineous healthy parents presented seizure and developmental regression. He was well until 6 months of age when he developed fever associated with one episode of seizure. Since the age of 2 years, he started to have frequent episodes of generalized tonic clonic seizures (GTCS) without fever (afebrile seizures). His general physical and neurological examination was normal. His psychological examination revealed a good space-temporal orientation and social interaction. Motor examination revealed normal strength and muscle tone in all extremities. By the age of 2 years 6 month, he had experienced approximately 10 episodes of GTCS per day with 1-hour interval between seizures, lasting 1--2 minutes. His seizures had improved with 400 mg sodium valproate and 150 mg syrup carbamazepine. The frequency of his seizures had varied from seizure free to several episodes per day. His parents had noticed that his seizures were exacerbated 5--6 am during his sleeping and at day time. Since then, he gradually experienced acute cerebellar ataxia with instability during walking and his developmental and speech gradually regressed and there were no signs of improvement. At the same time, his speech worsened from few words to bubbling. His electroencephalogram (EEG), computed tomography (CT) scan, and magnetic resonance imaging (MRI) brain at 8 years of age were normal. Currently, he continues to experience GTCS approximately 2--3 times every month, with abrupt onset and characterized by impairment of consciousness. Those seizures lasted about 1--2 minutes and aborted spontaneously. The doses of carbamazepine were increased to 300 mg and topiramate 25 mg was added to control the seizure, which did not decrease the frequency of the seizures. His current intellectual disabilities revealed mental retardation, developmental delay and autism features. At 11 years, he was still unable to speak with no verbal communication. His other neurological impairments included motor skills, social interaction skills, processing skills, learning, and memory. During our observations, he enjoys playing by himself and was not aware of his surroundings. His repeated EEG at 11 years of age showed abnormal record with a slowing of the background for age with absence of alpha activity, and the abnormal epileptic record showed frequent burst of epileptic discharges over both centro-parietal regions. At 15 years of age, his motor skill had improved with physiotherapy. Currently, he is able to walk without support. Unfortunately, his social skills remain poor, as he still has no social interaction. He did not attend school and his carbamazepine has been substituted to carbamazepine CR 400 mg and increased topiramate doses of 37.5 mg to reduce the symptomatology. His chromosomal karyotype showed no abnormalities (46, XY). Mutational analysis for *SCN1A* revealed a novel heterozygous point mutation a c.5197 A \> G transition in exon 26 of *SCN1A*. Consequently, the mutation was considered to be a pathogenic and *de novo* mutation.

Discussion {#sec1-3}
==========

In the GEFS+ syndrome, the most common generalized epilepsy phenotypes were febrile seizure plus (FS+).\[[@ref3]\] *SCN1A* is the most widely reported and clinically relevant gene for GEFS+ spectrum and also have been associated with a spectrum of epilepsy phenotype that includes severe myoclonic epilepsy of infancy (SMEI) and infantile spasms.\[[@ref7][@ref12]\] In addition to FS+, there are various generalized epilepsy phenotypes such as absences, myoclonic seizures, and myoclonic-astatic epilepsy. Here, we describe a patient with a novel *de novo* missense mutation (c.5197A \> G) \[[Figure 1](#F1){ref-type="fig"}\], which is inferred to have caused substitution of amino acid asparagines to aspartate in *SCN1A*. The clinical manifestation of the patient was consistent with febrile seizures and afebrile GTCS. Other clinical presentations were observed including a developmental delay, mental retardation, social anxiety and autism features.

![Direct DNA sequencing of *SCN1A* exon 26. The patient carried a c.5197A \> G in SCN1A exon 26, which led to substitution of asparagines with aspartate at amino acid 1733 (*P*. N1733D). The arrow indicates c.5197A \> G](JPN-7-123-g001){#F1}

We report a comprehensive clinical and genetic study of a patient with no history of GEFS+; our mutation analysis study revealed that our patient has a *de novo* heterozygous c.5197A \> G transition in exon 26 *SCN1A* molecule (domain IV, S5-S6; N1733D), located in the functionally pore regions of *SCN1A* (S4-S6). Certainly, we want to highlight the identification of a novel N1733D mutation for this unfortunate patient in the loop between segments S5 and S6 in the pore-forming region of domain IV of sodium channel which is consistent with the previous findings that occurrence mutation in the pore regions of *SCN1A* can lead to severe epileptic phenotypes as in previous literature by Pineda-Trujillo N *et al*. (2005). Interestingly, this boy also had the same variants like that observed in six patients with autism.\[[@ref13][@ref14]\] Reported by Kanai K. *et al*. in 2004, the majority of mutation in the pore-forming loop regions between S5 and S6 have been identified in patients with SMEI. That previous study reported that missense mutation in the pore regions of *SCN1A* was associated with a more severe phenotype because of the alteration of the pore and significantly affects the function of the sodium channel.\[[@ref15]\] The study from the French group in 2009 has brought new evidence that highly conserved amino acids located in ion transport sequences were affected by missense mutation which lead to chemical changes in amino acid and its functioning.\[[@ref16]\]

Four other reports of missense mutation in *SCN1A* gene associated with GEFS+ located in the loop between segments S5 and S6 are identified to date. The first mutation was discovered by Sugawara *et al*. in 2001: in GEFS+ patients with febrile seizures exhibiting afebrile partial epilepsy (domain III, S5-S6;V1428, C4283T).\[[@ref9]\] The second mutation was reported in a South American family: sequencing of the *SCN1A* gene revealed a novel missense mutation of aspartic acid to glycine, the amino acid replacement located in the pore-forming region of domain IV of *SCN1A* (domain IV, S5-S6;D1742G). The variable phenotypic expressions were observed including febrile seizures, GTCS, and mental retardation.\[[@ref17]\] The third mutation was identified in a patient with no family history available. The patient now is 6 years old with well controlled seizures and normal neurological development (domain I, S5-S6;R377Q).\[[@ref18]\] The fourth mutation identified by Mahoney *et al*. in 2009 also described a variable neurologic phenotype in a GEFS+ family that expanding the GEFS+ spectrum to include neuropsychiatric disease with a novel c1162T \> C mutation in *SCN1A* molecule (domain I, S5-S6;Y388H).\[[@ref19]\]

The variable expressivity observed in GEFS+ associated with *SCN1A* mutations remains a big challenge and interesting to discover in future. Further investigation is necessary to elucidate how the disease phenotype is determined in GEFS+ spectrum where many mechanisms, environmental factors or genetic factors could be involved in altering the sodium channel properties and function that lead to various clinical manifestation of GEFS+.\[[@ref15][@ref17]\] The presence of this case is important as a starting point for genetic testing in idiopathic generalized epilepsies, i.e., generalized epilepsy with febrile seizure plus (GEFS+), to prepare us for the possibility of exact diagnosis and challenges in counseling the families of the patients in future.
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